JEFFREY COLE is listed as an executive officer on 3 SEC Form D filings by 1 issuer between Dec 2025 and Jul 2026: Cadrenal Therapeutics, Inc. (Ponte Vedra, FL — biotechnology — 2025–2026; $9.43M reported sold to 5 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Glynn Wilson (3 shared filings), JAMES J. FERGUSON (3 shared filings), John R. Murphy (3 shared filings), Lee Golden (3 shared filings), Quang Pham (3 shared filings) and 3 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around JEFFREY. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 7 bankruptcy cases matching the name listed in Key records below.
What this means 7 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for JEFFREY COLE and found 4 differences: JEFFREY COLE is written 2 different ways on the filings; Same name, different state: "Jeffrey Cole" (A6) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.